Specify a stock or a cryptocurrency in the search bar to get a summary
enGene Holdings Inc. Common Stock
ENGNenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. Address: 7171 Rue Frederick Banting, Saint-Laurent, QC, Canada, H4S 1Z9
Analytics
WallStreet Target Price
30.57 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ENGN
Dividend Analytics ENGN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ENGN
Stock Valuation ENGN
Financials ENGN
Results | 2019 | Dynamics |